New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
07:59 EDTROSGRosetta Genomics platform predicts bladder cancer progression in published study
Rosetta Genomics announces the publication of clinical data in an article entitled, "The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer." The study profiled and analyzed microRNA expression levels in 86 samples of non-muscle-invasive bladder cancer to identify patterns of expression that are indicative of a high probability of disease progression. The main finding showed that in the least invasive tumors, low expression levels of miR-10a are correlated to later recurrence of the disease in a more invasive form. According to study author, Ulrika Segersten, Ph.D., Department of Surgical Sciences, Uppsala University, Uppsala, Sweden, "Profiling revealed that certain microRNAs predicted the risk of developing higher stage among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could have a crucial role for later invasion of non-invasive bladder tumors."
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 4, 2014
08:20 EDTROSGRosetta Genomics to receive U.S. patent for cancer origin assay
Rosetta Genomics announced that the company received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering the method of use of a core element of Rosetta Genomics' microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer. The issued claims for U.S. Patent Application No. 13/167,489 is entitled "Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use